GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

Central Pennsylvania is part of GSK ‘s recent announcement that it is investing $30 billion in R&D and manufacturing in the ...

SCYNEXIS ( (SCYX) ) has shared an update. On October 14, 2025, SCYNEXIS and GSK signed a binding memorandum of understanding to amend their exclusive license agreement, resolving a prior disagreement ...

GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...

GSK's Nashik facility achieves BSI AMR Kitemark certification for antibiotic manufacture, addressing global public health ...

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc announced an increase in notional interest in its ordinary shares for ...

GSK CEO Emma Walmsley will step down in January, with Luke Miels taking over amidst looming US tariffs on branded ...

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the ...

Dr. Emmanuel Hanon will be focused on advancing Viome's precision therapeutics platform intended to prevent chronic diseases, cancer, and aging. BELLEVUE, Wash., April 15, 2021 /PRNewswire/ -- Viome, ...

The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities ...

LONDON - GlaxoSmithKline [LSE: GSK] today reinforced its commitment to responsible management of ethical, social and environmental concerns and, in particular, to play a leading role in supporting ...